Golden eagle optimized CONV-LSTM and non-negativity-constrained autoencoder to support spatial and temporal features in cancer drug response prediction DOI Creative Commons
Wesam Ibrahim Hajim, Suhaila Zainudin, Kauthar Mohd Daud

и другие.

PeerJ Computer Science, Год журнала: 2024, Номер 10, С. e2520 - e2520

Опубликована: Дек. 23, 2024

Advanced machine learning (ML) and deep (DL) methods have recently been utilized in Drug Response Prediction (DRP), these models use the details from genomic profiles, such as extensive drug screening data cell line data, to predict response of drugs. Comparatively, DL-based prediction approaches provided better features. However, prior knowledge, like pathway is sometimes discarded irrelevant since datasets are multidimensional noisy. Optimized feature extraction processes suggested handle this problem. First, noise class imbalance problems must be tackled avoid low identification accuracy, long times, poor applicability. This article aims apply Non-Negativity-Constrained Auto Encoder (NNCAE) network tackle issues, enhance adaptive search for optimal size sliding windows, ensure that architectures adept at vital hidden NNCAE methodology used after performing standard pre-processing procedures balanced noise-removed input features learned train proposed hybrid classifier. The classification model, Golden Eagle Optimization-based Convolutional Long Short-Term Memory neural networks (GEO-Conv-LSTM), assembled by integrating Neural Network CNN LSTM models, with parameter tuning performed GEO algorithm. Evaluations conducted on two large Genomics Sensitivity Cancer (GDSC) repository, NNCAE-GEO-Conv-LSTM-based approach has achieved 96.99% 97.79% accuracies, respectively, reduced processing time error rate DRP

Язык: Английский

Hallmarks of cancer resistance DOI Creative Commons
Muhammad Tufail,

Jia-Ju Hu,

Jie Liang

и другие.

iScience, Год журнала: 2024, Номер 27(6), С. 109979 - 109979

Опубликована: Май 15, 2024

This review explores the hallmarks of cancer resistance, including drug efflux mediated by ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized Warburg effect, and dynamic interplay between cells mitochondria. The role stem (CSCs) in treatment resistance regulatory influence non-coding RNAs, such as long RNAs (lncRNAs), microRNAs (miRNAs), circular (circRNAs), are studied. chapter emphasizes future directions, encompassing advancements immunotherapy, strategies to counter adaptive integration artificial intelligence for predictive modeling, identification biomarkers personalized treatment. comprehensive exploration these provides a foundation innovative therapeutic approaches, aiming navigate complex landscape enhance patient outcomes.

Язык: Английский

Процитировано

18
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer DOI
Muhammad Tufail,

Wendong Wan,

Canhua Jiang

и другие.

Chemico-Biological Interactions, Год журнала: 2024, Номер 396, С. 111055 - 111055

Опубликована: Май 17, 2024

Язык: Английский

Процитировано

10
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence DOI Creative Commons
Muhammad Tufail, Canhua Jiang, Ning Li

и другие.

Military Medical Research, Год журнала: 2025, Номер 12(1)

Опубликована: Фев. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Язык: Английский

Процитировано

1
A Comprehensive Review of Nanoparticle-Based Drug Delivery for Modulating PI3K/AKT/mTOR-Mediated Autophagy in Cancer DOI Open Access
Md. Ataur Rahman, Maroua Jalouli,

Sujay Kumar Bhajan

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1868 - 1868

Опубликована: Фев. 21, 2025

The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway plays a crucial role in regulation autophagy, cellular mechanism vital for homeostasis through degradation damaged organelles and proteins. dysregulation this is significantly associated with cancer progression, metastasis, resistance to therapy. Targeting PI3K/AKT/mTOR signaling presents promising strategy treatment; however, traditional therapeutics frequently encounter issues related nonspecific distribution systemic toxicity. Nanoparticle-based drug delivery systems represent significant advancement addressing these limitations. Nanoparticles enhance bioavailability, stability, targeted therapeutic agents, facilitating precise modulation autophagy cells. Functionalized nanoparticles, such as liposomes, polymeric metal-based nanocarriers, facilitate tumor tissues, minimizing off-target effects improving efficacy. These can deliver multiple agents concurrently, enhancing PI3K/AKT/mTOR-mediated oncogenic pathways. This review examines advancements nanoparticle-mediated that pathway, emphasizing their contribution precision side integration nanotechnology molecularly therapies substantial potential resistance. Future initiatives must prioritize optimization clinical translation patient outcomes.

Язык: Английский

Процитировано

1
PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study DOI Creative Commons
Min Yan,

Zhiqiang Zong,

Wenyue Guo

и другие.

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Фев. 27, 2025

PIK3CA gene mutations have been identified in various malignancies, but the prevalence of specific and their role breast cancer development remain uncertain. This study aimed to investigate clinicopathological significance prognostic impact cancer. Five common (H1047R H1047L exon 20, E542K, E545K, E545D 9) were patients using amplification refractory mutation system (ARMS) allele-specific PCR. The examined relationships between these clinicopathologic factors, such as age, HR status, Her2 lymph node involvement, distant metastasis, stage, progression-free survival (PFS). A total 40 female included this study. Twenty detected, with 12 located 20 8 9. most frequent was H1047R present 11 (14.8%). more commonly observed + (P < 0.05). No significant correlation found or Ki-67 expression. Database analysis from cBioPortal online database showed that median PFS (95%CI) unaltered group [22.93 (17.25–48.30) months] higher than altered [12.98 (8.18–18.14) months]. In study, mutant-type [13.00 (10.56–15.45) had lower wild-type [25.00 (13.46–36.55) all patients, difference = 0.004). Further, compared wild-type, associated poor addition, positive Our data public research show is a change cancer, shorter all, patients. confirmed important

Язык: Английский

Процитировано

0
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond DOI
Durre Aden, Samreen Zaheer, Niti Sureka

и другие.

Pathology - Research and Practice, Год журнала: 2025, Номер 269, С. 155864 - 155864

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Comparative analysis of the genomic and expression profiles of ANLN and KDR as prognostic markers in breast Cancer DOI Creative Commons
Aamir Mehmood,

Rongpei Li,

Aman Chandra Kaushik

и другие.

In Silico Pharmacology, Год журнала: 2025, Номер 13(1)

Опубликована: Янв. 15, 2025

Язык: Английский

Процитировано

0
Understanding of chemotherapeutic resistance: With special reference to breast cancer DOI
Harmanjit Singh, Dwividendra Kumar Nim, Pankaj Kumar

и другие.

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 173 - 206

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Molecular Docking Appraisal of Pleurotus ostreatus Phytochemicals as Potential Inhibitors of PI3K/Akt Pathway for Breast Cancer Treatment DOI Creative Commons
Magdalene Eno Effiong, Mercy Bella-Omunagbe, Israel Sunmola Afolabi

и другие.

Bioinformatics and Biology Insights, Год журнала: 2025, Номер 19

Опубликована: Янв. 1, 2025

Introduction: Breast cancer (BC) is a heterogeneous disease involving network of numerous extracellular signal transduction pathways. The phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (Akt)/mechanistic target rapamycin (mTOR) pathway crucial for understanding the BC development. Phosphoinositide 3-kinase, phosphatase and tensin homolog (PTEN), mTOR, Akt, 3-phosphoinositide-dependent 1 (PDK1), FoxO1, glycogen synthase 3 (GSK-3), mouse double minute 2 (MDM2), H-Ras, proapoptotic B-cell lymphoma (BCL-2) family protein (BAD) proteins are key drivers this potential therapeutic targets. Pleurotus ostreatus an edible mushroom that rich in flavonoids phenols can serve as inhibitors PI3K/Akt/mTOR pathway. Aim: This study evaluated anticancer properties P through structure-based virtual screening 22 biologically active compounds present mushroom. Method: Model optimization was carried out on PI3K, PTEN, PDK1, GSK-3, MDM2, BAD molecular docking compounds/control binding pocket were simulated AutoDock Vina PyRx. drug likeness, pharmacokinetic, pharmacodynamic features prospective leads all anticipated. Result: Several potent selected driver identified from ostreatus. Ellagic acid with affinities −8.0, −8.1, −8.2, −6.2, −7.1 kcal/mol BAD, respectively, had better affinity compared their reference drugs. Likewise, apigenin (−7.8 kcal/mol), chrysin quercetin (−6.4 chlorogenic (−6.2 kcal/mol) to H-Ras proteins, respectively. Conclusion: acid, apigenin, luteolin, quercetin, chrysin, naringenin phytochemicals seen lead molecules due ability strongly bind under Analogs these also be designed

Язык: Английский

Процитировано

0
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy DOI Creative Commons
Pankaj Garg, Sravani Ramisetty, Meera G. Nair

и другие.

Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116850 - 116850

Опубликована: Март 1, 2025

Breast cancer (BC) is a complex disease that affects millions of women worldwide. Its growing impact calls for advanced treatment strategies to improve patient outcomes. The PI3K/AKT/mTOR pathway key focus in BC therapy because it plays major role important processes like tumor growth, survival, and resistance treatment. Targeting this could lead better options present review explores how the becomes dysregulated BC, focusing on genetic changes PIK3CA mutations PTEN loss leads its aggravation. Current include use inhibitors targeting PI3K, AKT, mTOR with combination therapies showing promise overcoming drug improving effectiveness. Looking ahead, next-generation personalized plans guided by biomarker analysis may provide more accurate effective patients. Integrating these immunotherapy offers an exciting opportunity boost anti-tumor responses survival rates. This comprehensive summary current progress BC. It highlights future research directions therapeutic aimed at enhancing outcomes quality life.

Язык: Английский

Процитировано

0